The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel ...

The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial. ・Durability signals were notable, with 68% of BCG-unresponsive patients and 66 ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Relmada Therapeutics, Inc. is one of them. Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...

Johnson & Johnson (JNJ) announced new data from an open-label, multicenter Phase 1 study evaluating Erda-iDRS, an investigational intravesical drug-releasing system with ...

Detailed price information for Theralase Techs Inc (TLTFF) from The Globe and Mail including charting and trades.